Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells

Background. This study was conducted to investigate the effect of alpha-fetoprotein (AFP) ratio on the prognosis of AFP-positive hepatocellular carcinoma (HCC) patients after hepatectomy. Methods. We retrospectively included 879 HCC patients with AFP-positive who underwent hepatectomy from February 2012 to October 2017 and randomly divided into training cohort and validation cohort. AFP ratio was equal to the AFP level within one week before hepatectomy to AFP level within 20-40 days after surgery. The end point of follow-up was disease-free survival (DFS) and overall survival (OS). Results. AFP ratio was not associated with clinical characteristics in training cohort and validation cohort. According to the X-tile software, the optimum cut-off point was 17.8 for AFP ratio. Significant differences between AFP ratio high and AFP ratio low were observed in DFS and OS in both cohort ( p < 0.05 ). Kaplan-Meier curves and receiver-operating curves were showed that AFP ratio was better than AFP level preoperation in predicting the prognosis of AFP-positive HCC patients after hepatectomy. The multivariate analysis demonstrated that AFP ratio was a significant independent risk factor for both OS and DFS in HCC patients with AFP-positive. Conclusions. AFP ratio might be a prognosis predictor for HCC patients with AFP-positive after hepatectomy.

Download Full-text

Tumor-derived alpha-fetoprotein (tAFP) causes immune and metabolic dysfunction in monocyte-derived dendritic cells

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-3-s2-p210 ◽

2015 ◽

Vol 3 (S2) ◽

Author(s):

Patricia M Santos ◽

Angela Pardee ◽

Greg M Delgoffe ◽

Lisa H Butterfield

Keyword(s):

Dendritic Cells ◽

Alpha Fetoprotein ◽

Metabolic Dysfunction

Download Full-text

Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears

Disease Markers ◽

10.1155/2010/912845 ◽

2010 ◽

Vol 28 (3) ◽

pp. 125-135

Author(s):

James N. Riggins ◽

William Corey ◽

Alfred N. Fonteh ◽

Michael G. Harrington

Keyword(s):

Tumor Suppressor ◽

Binding Protein ◽

Protein A ◽

Hepatocellular Cancer ◽

Alpha Fetoprotein ◽

Reverse Phase ◽

Enhancer Binding Protein ◽

Hepatic Carcinogenesis ◽

Serum Alpha Fetoprotein ◽

Chronic Hbv

Chronic hepatitis increases the risk of hepatocellular carcinoma (HCC). To test whether circulating proteins reflect hepatic carcinogenesis, sera from patients and controls were albumin depleted, enriched for glycoproteins, digested with trypsin, and subjected to reverse phase chromatography and tandem mass spectrometry. Alpha-fetoprotein enhancer binding protein (AFPebp), a tumor suppressor, was repeatedly identified in sera from chronic HBV hepatitis patients. We independently identified and quantified AFPebp with a deuterated, phenylisocyanate-labeled synthetic peptide standard. Elevated AFPebp levels in sera from chronic HBV hepatitis patients decreased as cancer developed. These data suggest that rising AFPebp levels in chronic HBV hepatitis may be protective, while falling levels may contribute to HCC development.

Download Full-text